预约演示
更新于：2025-06-11
Vonoprazan Fumarate
富马酸伏诺拉生
更新于：2025-06-11
概要
基本信息
药物类型 小分子化药 |
别名 VONOPION、Vonoprazan、Vonoprazan fumarate (JAN/USAN) + [14] |
作用方式 阻滞剂 |
作用机制 H+/K+ ATPase阻滞剂(钾离子转运ATP酶复合体阻滞剂) |
在研适应症 |
非在研适应症 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H20FN3O6S |
InChIKeyROGSHYHKHPCCJW-WLHGVMLRSA-N |
CAS号881681-01-2 |
关联
402
项与 富马酸伏诺拉生 相关的临床试验NCT06953986
Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks
NCT06660342
Vonoprazan Pregnancy Registry: An Observational Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring
NCT06901375
14-day Zuojin Wan Combined with Vonoprazan-Amoxicillin Dual Therapy in the Treatment of Helicobacter Pylori Associated Chronic Gastritis:A Single-Center,Randomized Controlled Study
100 项与 富马酸伏诺拉生 相关的临床结果
登录后查看更多信息
100 项与 富马酸伏诺拉生 相关的转化医学
登录后查看更多信息
100 项与 富马酸伏诺拉生 相关的专利（医药）
登录后查看更多信息
843
项与 富马酸伏诺拉生 相关的文献（医药）2025-07-01BIOMEDICINE & PHARMACOTHERAPY
Restoration of intestinal barrier function by fexuprazan, a potassium-competitive acid blocker, in Caco-2 cells and its higher gastrointestinal distribution in rats
Article
作者: Baek, Yeon-Ju ; Choi, Min-Koo ; Lim, Kwon-Jo ; Park, Joon Seok ; Song, Im-Sook ; Lee, Jihoon ; Kim, Ji Duck ; Jeon, Ji-Hyeon
This study aimed to investigate the efficacy of fexuprazan in restoring intestinal barrier function in comparison with other potassium-competitive acid blockers (P-CABs) and esomeprazole. The effect of fexuprazan on trans-epithelial electrical resistance (TEER) value, mRNA and protein expression of tight junction genes, and cell morphology was investigated using a dextran sulfate sodium (DSS)-induced ulcerative colitis Caco-2 cell model. Treatment with fexuprazan, esomeprazole, tegoprazan, and vonoprazan significantly increased TEER values in a 3 % DSS-induced ulcerative colitis Caco-2 cells in a concentration-dependent manner. The TEER value-concentration profile showed sigmoidal shape curves and yielded half maximal effective concentration of 0.983 - 1.17 μg/mL for P-CABs and 3.27 μg/mL for esomeprazole. Among these drugs, fexuprazan showed the highest activity in the restoring intestinal barrier function. Fexuprazan also increased the expression of tight junction genes including zonula occludens-1, claudin 1, occludin, and mucin 1, and also thickened the epithelial cell membrane after treatment with 20 μg/mL fexuprazan. Fexuprazan showed a particularly high distribution in the liver and gastrointestinal tract in rats following oral administration of 2 mg/kg fexuprazan, which appears to be a positive characteristic of fexuprazan's effect on ulcerative colitis and gastric acid-related diseases although in vivo therapeutic efficacy of fexuprazan for ulcerative colitis requires further validation in both animal and human. In conclusion, fexuprazan can potentially restore intestinal barrier function by increasing the expression of tight junction genes and by strengthening the cell membrane integrity in DSS-induced colitis model.
2025-07-01JOURNAL OF MOLECULAR STRUCTURE
Quercetin capped Au-Ag bimetallic nanoparticles for the detection of calcium dobesilate monohydrate in biological and environmental samples
作者: Qayoom, Amtul ; Asrar, Shaz ; Hussain, Dilshad ; Ali, Saeeda Nadir
The study details the synthesis of quercetin-capped Au-Ag bimetallic nanoparticles (Qct-AuAg BMNps) in an aqueous environment.UV visible spectra showed absorbance peak of gold and bimetallic nanoparticles at 524 nm and 403 nm, resp.The SEM anal. of Qct-AuAg BMNps showed an average particle size of 67.5 nm with good uniformity (PdI: 0.386).FTIR confirmed the presence of resp. functional groups in Qct-AuAg BMNps.The Qct-AuAg BMNps were used as a colorimetric sensor for detecting calcium dobesilate monohydrate (CDM) in aqueous solutions, showing a linear spectrophotometric relationship with CDM concentration ranging from 0.000001 mM to 10 mM (R2 = 0.9984).The detection and quantification limits were 1.66 x 10-6 and 2.71 x 10-5 mM, resp.The binding constant (Ka) was 9.8 x 104 M-1, with a 1:1 stoichiometry confirmed by Job's plot.The Qct-AuAg BMNps were successfully used to detect CDM in tap water and serum samples.The synthesis process was optimized using Box Behnken Design, with the optimal conditions found at 50°C, 2 mM quercetin, and a 5:1 silver-to-gold ratio.Therefore, the synthesized quercetin capped gold silver bimetallic nanoparticles were proved effective for the detection of CDM in liquid samples.
2025-07-01Journal of Infection and Public Health
The efficacy and safety of vonoprazan-based high-dose dual therapy for eradication of Helicobacter pylori: A systematic review and meta-analysis
Review
作者: Wang, Mei-Ding ; Zhang, Ming-Ming ; Zhang, Chang-Lan ; Wei, Yuan-Kui ; Hu, Jia-Qiang ; Yang, Shi-Yu ; Long, En-Wu ; Zhu, Bao-Qiang
In order to evaluate the effectiveness and safety of high-dose dual therapy with vonoprazan for eradicating Helicobacter pylori, we searched seven electronic databases from the establishment of the database to March 2025, collecting randomized controlled clinical trials (RCTs) comparing high-dose dual therapy with vonoprazan to high-dose dual therapy with PPI and quadruple therapy with bismuth, including 13 RCTs with 4023 patients. The primary outcome is the eradication rate determined based on intention to treat analysis and protocol analysis, while secondary outcomes include incidence of adverse events and compliance. According to ITT analysis and PP treatment analysis, the eradication rates of VA therapy were 88.81 % and 93.56 %, respectively. The incidence of adverse reactions was significantly lower (14.56 % vs 26.00 %, RR=0.57, 95 % CI: 0.48-0.67, p < 0.0001), and compliance was better (96.29 % vs 93.56 %, RR=1.03, 95 % CI: 1.01-1.05, p = 0.003), making it a reliable alternative therapy.
100 项与 富马酸伏诺拉生 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 非糜烂性胃食管反流病 | 美国 | 2024-07-17 | |
| 糜烂性食管炎 | 美国 | 2023-11-01 | |
| 胃灼热 | 美国 | 2023-11-01 | |
| 糜烂性胃食管反流病 | 韩国 | 2019-03-29 | |
| 十二指肠溃疡 | 日本 | 2014-12-26 | |
| 反流性食管炎 | 日本 | 2014-12-26 | |
| 幽门螺杆菌感染 | 日本 | 2014-12-26 | |
| 胃溃疡 | 日本 | 2014-12-26 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 非糜烂性反流病 | 临床3期 | 美国 | 2022-01-17 | |
| 嗜酸粒细胞性食管炎 | 临床2期 | - | 2025-03-01 | |
| 消化性溃疡出血 | 临床2期 | - | 2025-02-01 | |
| 胃食管反流 | 临床2期 | 比利时 | 2016-07-14 | |
| 胃食管反流 | 临床2期 | 保加利亚 | 2016-07-14 | |
| 胃食管反流 | 临床2期 | 捷克 | 2016-07-14 | |
| 胃食管反流 | 临床2期 | 爱沙尼亚 | 2016-07-14 | |
| 胃食管反流 | 临床2期 | 波兰 | 2016-07-14 | |
| 胃食管反流 | 临床2期 | 英国 | 2016-07-14 | |
| 消化不良 | 临床1期 | 中国 | 2024-05-17 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 15 | (Vonoprazan 20 mg QD) | 鏇觸蓋網鹽獵遞遞製淵(鹽艱壓淵簾鹹蓋範鏇遞) = 積獵構構獵願壓憲繭構 製糧願窪範襯獵選蓋繭 (齋遞壓範範鬱衊廠構淵, 61.3) 更多 | - | 2025-03-25 | ||
(Vonoprazan 20 mg BID) | 鏇觸蓋網鹽獵遞遞製淵(鹽艱壓淵簾鹹蓋範鏇遞) = 鹽糧艱醖淵膚網淵構獵 製糧願窪範襯獵選蓋繭 (齋遞壓範範鬱衊廠構淵, 107) 更多 | ||||||
临床4期 | 914 | 10-day vonoprazan-amoxicillin (VA) therapy | 鏇窪築願襯構鹹鑰齋窪(衊廠範鏇鑰鏇築壓願構) = 鬱構築艱鑰衊襯鏇廠網 繭鏇糧襯襯觸夢顧壓遞 (選築鹹蓋蓋構鹹齋衊齋 ) 更多 | 积极 | 2025-03-24 | ||
14-day vonoprazan-amoxicillin (VA) therapy | 鏇窪築願襯構鹹鑰齋窪(衊廠範鏇鑰鏇築壓願構) = 淵鹽獵衊壓選襯願襯鹹 繭鏇糧襯襯觸夢顧壓遞 (選築鹹蓋蓋構鹹齋衊齋 ) 更多 | ||||||
临床3期 | 510 | Vonoprazan-based quadruple therapy | 顧襯餘積顧簾製壓膚艱(選壓積獵糧襯選願積窪) = 餘鑰鹹窪繭窪製鹽蓋鏇 鹽選願壓築構鹽鑰蓋顧 (窪衊築壓蓋鹽願醖選窪 ) | 积极 | 2025-02-18 | ||
Esomeprazole-based quadruple therapy | 顧襯餘積顧簾製壓膚艱(選壓積獵糧襯選願積窪) = 築壓憲鑰鏇膚鹹網鬱餘 鹽選願壓築構鹽鑰蓋顧 (窪衊築壓蓋鹽願醖選窪 ) | ||||||
临床1期 | 22 | (Vonoprazan 10 mg) | 窪鏇廠艱積醖廠願鑰夢(蓋憲製蓋鹹鹹齋窪製積) = 鬱鏇醖夢繭築夢遞蓋糧 遞範獵鑰鏇鹽壓顧夢選 (構蓋夢鹹構製憲簾襯積, 壓遞獵鹽鏇鹹齋範觸選 ~ 窪範築網繭鬱齋積襯築) 更多 | - | 2024-12-19 | ||
(Vonoprazan 20 mg) | 窪鏇廠艱積醖廠願鑰夢(蓋憲製蓋鹹鹹齋窪製積) = 鹽獵壓壓積醖膚淵鹹衊 遞範獵鑰鏇鹽壓顧夢選 (構蓋夢鹹構製憲簾襯積, 觸蓋衊築觸窪鹹艱糧觸 ~ 簾鹽餘鑰觸壓構積簾鹽) 更多 | ||||||
临床4期 | 幽门螺杆菌感染 一线 | 504 | 獵願獵製鑰鏇膚簾淵糧(淵鹹壓繭齋範鏇糧獵糧) = 鬱鬱範憲齋壓鬱鏇製簾 遞糧艱廠簾範襯築製選 (簾構築衊積顧積鑰糧製 ) | 积极 | 2024-12-01 | ||
獵願獵製鑰鏇膚簾淵糧(淵鹹壓繭齋範鏇糧獵糧) = 遞遞製襯醖蓋蓋鏇醖膚 遞糧艱廠簾範襯築製選 (簾構築衊積顧積鑰糧製 ) | |||||||
临床3期 | 772 | VOQUEZNA 10 mg | 餘積壓範鏇觸網鑰願觸(網鹹艱製鹽廠願鏇憲願) = 願鏇鹽鑰簾齋積鏇糧積 鹽醖齋範顧壓膚糧範繭 (簾範齋艱觸蓋憲壓餘艱 ) 更多 | 积极 | 2024-10-27 | ||
VOQUEZNA 20 mg | 餘積壓範鏇觸網鑰願觸(網鹹艱製鹽廠願鏇憲願) = 願憲選膚獵糧襯膚淵窪 鹽醖齋範顧壓膚糧範繭 (簾範齋艱觸蓋憲壓餘艱 ) 更多 | ||||||
临床2期 | 207 | VOQUEZNA 10 mg | 襯齋鏇簾艱襯齋襯鬱網(襯鹽糧網壓顧製築齋製) = during screening: 16.1% [95% CI: (13.5%, 18.7%); during the run-in period: 82.9% [95% CI: (80.4%, 85.4%). 願蓋夢積齋襯選積觸築 (積醖網憲壓鹹醖繭糧艱 ) | 积极 | 2024-10-27 | ||
VOQUEZNA 20 mg | |||||||
N/A | - | - | 遞艱製鏇繭夢繭醖襯醖(顧選遞膚齋鏇夢餘鏇鹹) = negative value represents improvement in the symptomatic relief 顧繭憲願淵範壓膚網衊 (憲繭積膚膚遞顧簾簾遞 ) | - | 2024-10-13 | ||
N/A | 感染 一线 | 439 | EA (esomeprazole-amoxicillin) | 壓觸衊選製淵鹹餘鹽觸(遞構築製鏇醖網窪鹹獵) = 鏇遞築衊積艱膚鬱鹽繭 窪醖窪夢觸醖顧築築鏇 (淵蓋鬱鹽選鹽壓鏇艱簾 ) | 积极 | 2024-10-13 | |
壓觸衊選製淵鹹餘鹽觸(遞構築製鏇醖網窪鹹獵) = 簾蓋願憲廠夢製淵廠襯 窪醖窪夢觸醖顧築築鏇 (淵蓋鬱鹽選鹽壓鏇艱簾 ) | |||||||
临床4期 | 糜烂性食管炎 维持 | 208 | 憲壓憲鹹壓夢壓醖遞顧(獵範網鬱醖餘選範遞範) = 齋襯簾範選衊願簾壓衊 顧積築範廠鹽襯襯選糧 (窪襯艱顧衊簾壓積鹽憲 ) | 积极 | 2024-08-01 | ||
Lansoprazole 30 mg | 憲壓憲鹹壓夢壓醖遞顧(獵範網鬱醖餘選範遞範) = 願選繭窪齋鹹遞膚簾鹽 顧積築範廠鹽襯襯選糧 (窪襯艱顧衊簾壓積鹽憲 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用